Somatic mutations in STK11 and KEAP1 were related to decreased T cell–inflamed gene expression profile and have been proposed as biomarkers underlying ICIs resistance in patients with NSCLC [30, 31]. The gene discussed is STK11; the disease is non-small cell lung carcinoma.